• ScreenPro (SCRN) has received two new four-month service agreements from television productions
  • ScreenPro provides turnkey coronavirus screening solutions to the private sector including testing, track and tracing with GoStop alerting software
  • This platform allows ScreenPro to be a nationwide provider of full-service testing solutions across Canada
  • ScreenPro Security Inc. (SCRN) is up 5.88 per cent and is trading at C$0.090 at 12:57 pm ET

ScreenPro Security Inc. (SCRN) has received two new four-month service agreements from television productions for rapid testing.

ScreenPro will provide its newly introduced rapid tests and proprietary GoStop mobile alerting software.

CEO John McMullen remarked,

“To continue servicing our current clients and onboard new productions with this new test technology and COVID passport, GoStop, is a testament to the services ScreenPro provides. Through PCR and Rapid testing, we help businesses move forward.”

ScreenPro provides turnkey coronavirus screening solutions to the private sector including testing, track and tracing with GoStop alerting software.

ScreenPro’s unique access to multiple manufacturers of high-quality South Korean test kits and its strategic partnership with Canvas Labs in Vancouver and Integrated Explorations in Ontario.

This platform allows ScreenPro to be a nationwide provider of full-service testing solutions across Canada.

ScreenPro Security Inc. (SCRN) is up 5.88 per cent and is trading at C$0.090 at 12:57 pm ET.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.